Shirley, NY – Mar 4, 2026 – Creative Bioarray, a leader in advanced biomedical research solutions, focuses on developing industry-leading, lab-grown human tissue models and supporting products that enable researchers to replace, reduce, and refine animal testing. Recently, Creative Bioarray is proud to announce its flagship cutting-edge services: In Vitro and In Vivo Blood-Brain Barrier (BBB) Assays. These innovative assays are pivotal for evaluating drug permeability and transport mechanisms across the critical interface of the central nervous system (CNS).
“Our expertise in blood-brain barrier assays ensures that your project benefits from precise, reproducible results, aligned with the latest industry standards.” says Hannah Cole, spokesperson for Creative Bioarray. “Our new assays offer researchers the tools they need to understand not only the permeability of candidate drugs but also the mechanisms that govern their transport into the brain. Partner with Creative Bioarray to leverage cutting-edge BBB testing capabilities and accelerate your CNS therapeutic programs with confidence.”
As the pharmaceutical industry advances with novel therapeutic modalities that have the potential to treat or even cure certain brain diseases, e.g., adeno-associated virus (AAV)-mediated gene therapies, CAR-T cell therapies, and therapies based on CRISPR and other gene-editing technologies, the demand for a reliable human BBB model has never been greater. Creative Bioarray’s in vitro assays offer high-throughput, cost-effective screening capabilities for early-stage discovery, allowing for detailed mechanistic studies of drug transport.
Creative Bioarray’s In Vitro assays are designed to assess key endpoints, including permeability measurements, barrier integrity checks, and transporter activity evaluations, ensuring that drug candidates are assessed comprehensively. Creative Bioarray releases a number of in vitro models designed to mimic the BBB are used to study barrier function, both to screen new CNS drug candidates for BBB permeability and to shed light on how the BBB is regulated.
In in vivo studies, Creative Bioarray offers comprehensive research involving rodent models. These tests assess central nervous system exposure under conditions that highly simulate physiological environments. Through advanced sampling techniques, researchers can evaluate the behavior of compounds in real-world scenarios, gaining insights into drug distribution and clearance.
“Our integrated in vitro and in vivo platforms provide scientists with a complete guide from initial screening to advanced preclinical trials,” Hannah Cole added. “This integration is crucial for gaining a deeper understanding of how new therapies can effectively reach the brain.”
As the demand for effective central nervous system therapies continues to increase, Creative Bioarray is committed to supporting drug development research by leveraging innovative tools and its extensive experience in blood-brain barrier research.
About Creative Bioarray
Creative Bioarray has gradually becoming one of the leading biotechnology companies providing high quality cell culture products and specialized services, including 3D cell models and assay technologies for drug discovery and development. With a commitment to innovation and quality, Creative Bioarray supports researchers worldwide based on an experienced professional team and customized solutions for diverse research.
